EFPIA demands assessment of 'damaging' EU pharma legislation

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has unleashed a broadside against decision-makers in Brussels.

Proposals contained in the leaked draft of the European Union pharmaceutical legislation will do irreversible, long-term damage to the competitiveness of an industry that contributes more to the EU trade surplus than any other sector, the EFPIA warned in a scathing statement.

Setting the scene, the EFPIA underlined its understanding that competitiveness had been top of the agenda, citing last month’s conclusions of the Special meeting of the European Council, the recent meeting of the Competitiveness Council, the European Semester 2023 and President von der Leyen’s commitment to a standard competitiveness-check in regulation.